A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations
Clinical trial NCT06653842 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06653842
- Sponsor
- Palvella Therapeutics, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-12-20
- Primary completion
- 2025-11-21
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.